Warning: The NCBI web site requires JavaScript to function. more...
HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JM.
Breast Cancer Res. 2006;8(2):R19. Epub 2006 Apr 7.
Related citations
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2009;11(4):R50. Epub 2009 Jul 22.
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
Thor AD, Edgerton SM, Jones FE.
Am J Pathol. 2009 Nov;175(5):1802-9. Epub 2009 Oct 1.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB, Landt S, Bueler H, Kuehl U, Coupland S, Kleine-Tebbe A, Lichtenegger W, Schaller G.
Breast Cancer Res Treat. 2003 Nov;82(1):23-8.
Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR.
BMC Cancer. 2009 Nov 24;9:410.
The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.
Crit Rev Oncol Hematol. 2010 May;74(2):73-8. Epub 2009 May 30. Review.
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
Têtu B, Brisson J.
Cancer. 1994 May 1;73(9):2359-65.
p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC.
Cancer Res. 1994 Jul 15;54(14):3752-7.
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
Breast Cancer Res. 2009;11(1):R11. Epub 2009 Feb 24.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.
J Pathol. 2003 Jul;200(3):290-7.
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R.
Br J Cancer. 1994 Jun;69(6):1032-7.
Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G, Beadle G, Thomas S, Mengersen K, Stein S.
Pathology. 2006 Oct;38(5):391-8.
Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO.
Cancer. 2007 May 15;109(10):2016-24.
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2008;10(1):R2. Epub 2008 Jan 8.
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, Nam SJ, Bang S, Park J, Kim DH.
Breast Cancer Res. 2010;12(6):R100. Epub 2010 Nov 23.
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO.
Br J Cancer. 1996 Jul;74(2):229-33.
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.
Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, Rini BI, Bukowski RM, Zhou M.
Clin Genitourin Cancer. 2007 Mar;5(4):264-70.
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE.
Cancer Res. 2008 Aug 1;68(15):6387-95.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on